Congressman Don Davis announces new aviation education bill
ELIZABETH CITY, N.C. (WNCT) — Congressman Don Davis has proposed new legislation that would expand access to aviation education.
On Thursday, Congressman Davis introduced the Flight Education Access Act (H.R. 3530) at a press conference in his district office. The bill, which is co-led by VA Congresswoman Jen Kiggans, will raise the federal student loan limit for students enrolled in undergraduate flight training programs. A school that this would affect is Elizabeth City State University, as it is the only four year college that has an aviation program in North Carolina.
With this bill, dependent students could borrow up to $111,000 and independent students could borrow up to $137,500. The Department of Education will have to track and report how many students finish in the programs affected every year.
'By raising student loan limits for our aspiring pilots, we are taking one step towards meeting our nation's aerospace workforce needs and providing opportunities for the next generation across eastern North Carolina and our nation,' said Congressman Davis. 'We must do everything we can to create a brighter future for our aviation students, no matter their zip code or crossroad.'
Right after announcing the bill Congressman Davis attended the Our Community Salutes Event, a program that supports high school graduates who are enlisting in the US military.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Veterans' Benefits Protection Law Enacted in Florida: National Association for Veterans Rights Highlights Leadership of Governor DeSantis and State Legislature
WASHINGTON--(BUSINESS WIRE)-- The National Association for Veterans Rights (NAVR) commends Florida Governor Ron DeSantis and members of the Florida Legislature for enacting Senate Bill 910 (SB 910), known as the Safeguarding American Veteran Empowerment (SAVE) Act, into law. This significant measure enhances consumer protections for Veterans navigating the U.S. Department of Veterans Affairs (VA) benefits claims process. This legislation provides stronger oversight of free-market assistance by establishing clear fee caps, prohibiting upfront and nonrefundable charges, banning referral fees, and requiring thorough disclosures and background checks. These provisions aim to protect Veterans from predatory practices while preserving their right to seek open-market assistance. NAVR extends its sincere appreciation to State Senator Jay Collins, a disabled Veteran and tireless advocate, for his leadership in championing this critical legislation. NAVR also recognizes Representative Jon Albert and prime co-sponsor Representative Danny Alvarez for their essential roles in advancing the bill through the House. By signing this bill into law, Governor DeSantis joins a growing number of state leaders taking action to protect Veterans. Florida now aligns with several other states that have enacted similar legislation, including Alabama, Louisiana, Oklahoma, South Dakota, and Tennessee. 'NAVR commends Governor DeSantis for his leadership in safeguarding the rights and dignity of Florida's Veterans,' said Peter O'Rourke, President of NAVR, Veteran of both the U.S. Navy and U.S. Air Force, and former Acting Secretary and Chief of Staff of the VA. 'This new law represents a meaningful and timely step toward ensuring those who have served are treated fairly and protected when seeking the benefits they've earned.' NAVR supports state-based initiatives, such as SB 910, that enhance transparency, improve accountability, and provide Veterans with greater protections without expanding federal bureaucracy. These reforms reflect a growing bipartisan consensus that Veterans deserve the right to make informed decisions about their benefits with confidence and clarity. About NAVR: The National Association for Veterans Rights (NAVR) is a national trade association dedicated to promoting ethical and transparent business practices among companies that engage with the service-disabled Veteran community. NAVR advocates for businesses that empower Veterans with professional and transparent solutions while advancing support for Veteran-owned businesses.
Yahoo
7 hours ago
- Yahoo
Questions to ask a home loan lender
The home-buying process involves a lot of learning, from understanding your options to the ins and outs of making your first payment. Having a list of questions to ask your home loan lender can ensure a smoother experience. Aim to understand the types of mortgages the company offers and what to expect with the application process. You don't need a list of mortgage products. Instead, get the loan officer's perspective on the best option for you. Do you qualify for a conventional loan with more flexible loan terms? Or does a government-backed loan, like an FHA, USDA, or VA mortgage, make more sense for you? Lenders may also offer products or special programs for specific groups, such as first-time home buyers or borrowers with low incomes. Submitting all required documents can avoid delays in processing your application. You typically must provide recent pay stubs, income tax returns, and W-2 forms. If you're self-employed, expect to submit business tax returns or recent profit and loss statements. In a hot housing market, timing is everything. Ask the lender how long the application and approval process takes and how you can stay up-to-date on your application status. Online mortgage lenders may have faster processes, but not always. The length of time it takes varies based on the lender and the complexity of your financial situation. If there's any money you need to put down before closing, try to understand that sooner rather than later. While a 20% down payment will help you avoid private mortgage insurance (PMI) on conventional loans, you're often required to pay a lot less. You may be able to put down as little as 3% on a conventional loan and 3.5% for an FHA loan. VA and USDA mortgages don't have down payment requirements. Keep in mind that the less money you put down, the more you're borrowing. A higher loan amount means you'll pay more in interest and fees. Ask your lender if you qualify for their down payment assistance programs, if offered. If not, see if they'll help you navigate any national or local programs you may be eligible for. Down payment assistance can be in the form of a grant, forgivable loan, or a loan that's deferred until you sell or refinance the primary mortgage. These programs may be available for first-time home buyers, borrowers with a low income, or applicants who meet other criteria. Conventional loans usually only require private mortgage insurance if you put down less than 20%. However, you'll pay mortgage insurance on FHA and USDA mortgages regardless of the down payment. Make sure you understand the insurance requirements for the loan you choose. You'll come across several fees throughout the mortgage approval process. Many of them are due at closing. However, a mortgage provider can ask for certain fees before closing, like the application or origination fee. The interest and annual percentage rate (APR) largely determine how much it'll cost you to take on a mortgage. Ask these questions to know what you're getting into. Your mortgage interest rate depends on personal factors, like your credit score and income. But it's also determined by the lender's processes. That's why it's important to prequalify with more than one. But don't just look at the interest rate. Ask about your APR and what goes into it. The APR is often a better measure of the total cost of borrowing since it includes the interest rate plus lender fees or discount points. Many mortgage providers offer a rate lock, which can protect you from interest rate fluctuations during the loan approval process. While some lenders offer it for free, others may charge a fee. Understand the terms and costs with your loan advisor. Ask your lender to break down your monthly mortgage payment, which is often more than the principal and interest. Mortgage payments can also include mortgage insurance, property taxes, and homeowners insurance. The cash needed to close can be a hefty amount. Make sure you know what to expect. Closing costs are typically 2% to 5% of your loan, so you'll want a breakdown of the fees. Some of these costs are lender charges for processing your loan. Other fees go to the government or third parties who handle the appraisal, title search, and more. Once you understand your closing costs, ask the lender how you can lower them. Lenders have more control over their fees, so they may waive the application or origination fee if you ask. If you need to lower what you pay at closing, the lender may be able to roll the costs into the loan or apply a lender credit. With lender credits, you take a higher interest rate in exchange for lower or no closing costs up-front. Ask your lender how long it'll take to close the loan and whether the process is in person or if you can complete it online. 'Even if you don't need a quick close, it's a good question to ask, because it can indicate how prepared or on-the-ball the lender is,' said Ann O'Connell, attorney and legal editor at Nolo, via email. 'Of course, the speed at which the closing occurs also depends on the buyer getting all documentation to the lender in a timely manner.' Make sure you understand all the documents you'll need at closing. Your loan advisor should be able to provide the details needed for a smooth closing. These questions will give you an idea of what to expect when repaying your loan. Your loan servicer is the company that handles repayment. It may be the same lender that originated the loan, but sometimes lenders sell the mortgage to another institution. 'Many buyers aren't aware that lenders often sell the mortgage after closing, and that the loan might in fact be sold more than once, said O'Connell. 'By no means is this a reason to go with another lender. It just means that as a buyer, you'll need to stay on top of where you should send your mortgage payment each month.' Some lenders charge a prepayment penalty if you pay off your mortgage early. This can be a percentage of the remaining balance or a certain amount of interest. So if you plan to pay off your mortgage or sell your home within three or five years, this fee won't catch you off guard. First-time home buyers should ask about down payment assistance and other programs that can lower home-buying costs. They should also ask fundamental questions about the overall process, such as 'what requirements must I meet to qualify,' and 'what is preapproval versus prequalifying?' Prequalify with at least three lenders to get a good sense of the interest rate and loan amount you're eligible for. You can usually prequalify for a mortgage online by providing basic personal and financial information. While it's not a guarantee of approval or terms, you can compare offers and show the seller you're serious about buying. Before meeting with your mortgage lender, think through how much you plan to borrow and what down payment you can save. This will give the loan advisor an idea of your budget and borrowing needs. You can also gather important financial documents, like your recent pay stubs, W-2s, or income tax returns.
Yahoo
7 hours ago
- Yahoo
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologics advances toward its Phase 1/2 clinical trial for diabetic foot ulcers in the second half of 2025 and continues to expand its fibroblast-based therapeutic platform. 'Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn't just helpful — it's a force multiplier as we move our lead program into the clinic. He knows how to raise capital in a complex biotech environment, and that makes him a critical part of our mission to drive long-term innovation and deliver exceptional value to shareholders,' commented Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer. Mr. Davis added, 'FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases, and has all the elements of a high-growth, high-impact enterprise. I'm excited to bring my experience in public company finance to the table as we execute, scale, and deliver meaningful value — not just for shareholders, but for patients around the world.' Mr. Davis most recently served as Chief Financial Officer of Virax Biolabs, where he helped navigate the company through its successful IPO in July 2022. During his tenure, he led multiple capital raises with favorable terms, managed all periodic reports and other filings with the SEC, and implemented public company governance best practices. Prior to Virax, Mr. Davis served in various finance roles for several public companies, including HyperDynamics Corp, where he increased the company's market cap from $20 million to over $700 million and raised over $200 million in multiple transactions from U.S. and European capital markets. He received his B.B.A. in Accounting from the University of Houston and is a CPA certified in Texas. For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials, and the role to be played by, and impact of, the Chief Financial Officer. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)
